Baranovskiy Andrey G, Babayeva Nigar D, Suwa Yoshiaki, Gu Jianyou, Pavlov Youri I, Tahirov Tahir H
Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Nucleic Acids Res. 2014 Dec 16;42(22):14013-21. doi: 10.1093/nar/gku1209. Epub 2014 Nov 27.
Natural tetracyclic diterpenoid aphidicolin is a potent and specific inhibitor of B-family DNA polymerases, haltering replication and possessing a strong antimitotic activity in human cancer cell lines. Clinical trials revealed limitations of aphidicolin as an antitumor drug because of its low solubility and fast clearance from human plasma. The absence of structural information hampered the improvement of aphidicolin-like inhibitors: more than 50 modifications have been generated so far, but all have lost the inhibitory and antitumor properties. Here we report the crystal structure of the catalytic core of human DNA polymerase α (Pol α) in the ternary complex with an RNA-primed DNA template and aphidicolin. The inhibitor blocks binding of dCTP by docking at the Pol α active site and by rotating the template guanine. The structure provides a plausible mechanism for the selectivity of aphidicolin incorporation opposite template guanine and explains why previous modifications of aphidicolin failed to improve its affinity for Pol α. With new structural information, aphidicolin becomes an attractive lead compound for the design of novel derivatives with enhanced inhibitory properties for B-family DNA polymerases.
天然四环二萜类化合物阿非科林是B族DNA聚合酶的一种有效且特异性的抑制剂,它能阻止复制,并在人类癌细胞系中具有很强的抗有丝分裂活性。临床试验表明,由于阿非科林溶解度低且在人体血浆中清除速度快,其作为抗肿瘤药物存在局限性。缺乏结构信息阻碍了阿非科林类似物抑制剂的改进:到目前为止已经产生了50多种修饰,但所有这些修饰都失去了抑制和抗肿瘤特性。在此,我们报告了人类DNA聚合酶α(Pol α)催化核心与RNA引发的DNA模板及阿非科林形成的三元复合物的晶体结构。该抑制剂通过停靠在Pol α活性位点并旋转模板鸟嘌呤来阻止dCTP的结合。该结构为阿非科林与模板鸟嘌呤互补掺入的选择性提供了一种合理的机制,并解释了为什么之前对阿非科林的修饰未能提高其对Pol α的亲和力。有了新的结构信息,阿非科林成为设计对B族DNA聚合酶具有增强抑制特性的新型衍生物的有吸引力的先导化合物。